Please see below all current gastrointestinal cancer clinical trials of the Central Coast Cancer Centre.
Name: OXTOX
Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Colorectal Cancer
Name: INTEGRATE II
A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Gastrointestinal Cancer
More information about INTEGRATE II
Name: ASCOLT
ASPIRIN FOR DUKES C AND HIGH-RISK DUKES B COLORECTAL CANCERS
An International, Multi‐centre, Double-Blind, Randomised Placebo-Controlled Phase III Trial
Protocol Number: AG0213CR
Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Closed
Condition: Gastrointestinal/Colorectal Cancer
More information about ASCOLT
Name: DYNAMIC III COLON
DYNAMIC III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer. A Multicentre Phase II/III Randomised Controlled Study.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Colon Cancer
More information about DYNAMIC III
Name: DYNAMIC Rectal
A multicentre randomised study for circulating tumour DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Rectal Cancer
More information about DYNAMIC Rectal
Name: NABNEC
A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Gastric Cancer
More information about NABNEC
Name: Protocol 8951-CL-5201
A phase 2, open-label, randomized study to assess the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as first line treatment in subjects with Claudin 18.2 (CLDN 18.2) positive, metastatic pancreatic adenocarcinoma.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Pancreatic Cancer
More information about Protocol 8951-CL-5201
Name: SGNLV-005
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic solid tumours.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Gastrointestinal Cancer
More information about SGNLV-005
Name: Genescreen 5FU
A Pilot Study of Genotype-guided Personalised Fluoropyrimidine Dosing: Feasibility and Implimentation
Principal Investigator: Dr Craig Kukard
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastrointestinal Cancer
Name: MOUNTAINEER-02
A randomised, double-blind, placebo-controlled Phase II/III Study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with gastro eosophageal cancer
Principal Investigator: Dr Matthew Wong
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastro-Eosophageal Cancer
More information about MOUNTAINEER- 02
Name: MK 6482
An Open-label, multicentre, phase II study to evaluate the efficacy and safety of pembrolizumab plus lenvatinib in combination with belzutifan in multiple solid tumours.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Carcinoma, Hepatocellular, Colorectal Neoplasms, Biliary Tract Neoplasms, Pancreatic Ductal Ca
More information about MK 6482
Name: LARK
The LARK Clinical Trial Liver Ablative Radiotherapy utilising Kilovoltage Intrafraction Monitoring (KIM).
Principal Investigator: Dr Simon Tang
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Liver Cancer
More information
For more information about medical oncology clinical trials, please contact the Nurse Unit Manager on 02 4320 9890 or see:
Research and Clinical Trials